Established in 1997, S.L.A. Pharma AG is one of the few pharmaceutical companies in the world focused solely on developing medicines for the prevention and treatment of gastrointestinal disorders such as chemotherapy and radiotherapy induced diarrhoea, familial adenomatous polyposis (FAP), non-healing pilonidal sinus (PNS), anal fissures and inflammatory bowel disease. As a company specializing in gastrointestinal and allied diseases, S.L.A. Pharma AG is continually looking to expand its range of licensed products and those in clinical development, to treat gastrointestinal disorders worldwide.
This commitment to developing solutions for GI disorders has made S.L.A. Pharma a world leader in the field with unequalled development, medical, regulatory and commercial expertise in the therapeutic area and works closely alongside a global network of top gastroenterologists and colorectal surgeons. Collaboration with external partners is a core competence of SLA Pharma, who have a willingness to establish strategic partnerships for successful in-licensing or out-licensing initiatives.